一站式联合全身PSMA PET/CT与局部PET/mpMRI显像优化可疑前列腺癌患者治疗决策的研究

Study on optimizing treatment decisions for patients with suspected prostate cancer using one-stop combined whole-body PSMA PET/CT and local PET/mpMRI imaging

    摘要
  • 摘要:
    目的 评估全身前列腺特异性膜抗原（PSMA）PET/CT联合局部PET/多参数磁共振成像（mpMRI）（简称PSMA联合显像）在优化临床可疑前列腺癌（PCa）患者治疗决策中的价值。
    方法  收集2024年4月至11月于广州医科大学附属第一医院接受PSMA联合显像的110例可疑PCa患者的临床、影像及组织病理学检查资料，并进行观察性回顾性队列研究，患者年龄（73.0±7.4）岁。经PSMA联合显像排除远处转移的局限性PCa患者接受根治性前列腺切除术（RP），并以行RP患者的术后组织病理学检查结果为“金标准”，比较PSMA联合显像与mpMRI在PCa T分期、N分期诊断中的准确率。所有患者均经过PCa多学科诊疗团队集体阅片并制定治疗决策。采用精确McNemar检验比较PSMA联合显像与mpMRI对 PCa分期诊断的准确率。
    结果 110例可疑PCa患者中，4例（3.6%）患者经PSMA联合显像及术前穿刺活检确诊为良性前列腺增生，106例（96.4%）为临床显著性前列腺癌（csPCa），其中40例（37.7%，40/106）患者经PSMA联合显像未改变原治疗方案，行RP，66例（62.3%，66/106）调整了治疗方案，其中41例（38.7%，41/106）因发现远处转移，转为全身系统性治疗，其余25例（23.6%，25/106）因肿瘤T分期、N分期上调，在RP前行新辅助内分泌治疗。PSMA联合显像对PCa患者T分期的准确率62.5%（25/40）对 45.0%（18/40），χ2=4.000，P=0.020和N分期的准确率80.0% （32/40）对 67.5%（27/40），χ2=2.286，P=0.131均高于mpMRI 。
    结论 与mpMRI相比，PSMA联合显像改变了62.3%的PCa患者的临床治疗决策；PSMA联合显像可明显提高csPCa患者 T分期和N分期的准确率，为个体化精准诊疗提供依据。

     

    Abstract:
    Objective To evaluate the value of whole-body prostate specific membrane antigen (PSMA) PET/CT combined with local multi-parametric magnetic resonance imaging (mpMRI) (referred to as PSMA combined imaging) in optimizing therapeutic decision-making for patients with clinically suspected prostate cancer (PCa).
    Methods The clinical, imaging, and histopathological examination data of 110 patients with suspected PCa who underwent PSMA combined imaging at the First Affiliated Hospital of Guangzhou Medical University from April to November 2024 were collected for a observational retrospective cohort study. The patients were aged (73.0±7.4) years. Patients with local PCa without distant metastasis who were excluded by PSMA combined imaging underwent radical prostatectomy (RP). The postoperative histopathological examination results of patients who underwent RP were used as the "gold standard" to compare the accuracy rates of PSMA combined imaging and mpMRI in the diagnosis of PCa T staging and N staging. All patients underwent collective film review and treatment decision-making by a multi-disciplinary PCa diagnosis and treatment team. The accuracy rates of PSMA combined imaging and mpMRI in diagnosing PCa staging were compared using the exact McNemar test.
    Results Among the 110 suspected PCa patients, 4 patients (3.6%) were diagnosed as benign prostatic hyperplasia based on the results of PSMA combined imaging and preoperative puncture biopsy. The remaining 106 cases (96.4%) were clinically significant PCa (csPCa). Among the 106 csPCa patients, 40 patients (37.7%, 40/106) did not change their original treatment plans and underwent RP after PSMA combined imaging. The remaining 66 patients (62.3%, 66/106) adjusted their treatment plans. Among them, 41 patients (38.7%, 41/106) were transferred to systemic treatment due to the discovery of distant metastasis, while the remaining 25 patients (23.6%, 25/106) underwent neoadjuvant endocrine therapy before RP due to the elevation of tumor T and N staging. The accuracy rate of PSMA combined imaging for T staging in PCa patients (62.5% (25/40) vs. 45.0% (18/40), χ2=4.000, P=0.020) and the accuracy rate of N staging (80.0% (32/40) vs. 67.5% (27/40)) were higher than those of mpMRI (χ2=2.286, P=0.131).
    Conclusions Compared to mpMRI, PSMA combined imaging has altered the clinical treatment decisions for 62.3% of PCa patients; PSMA combined imaging can significantly improve the accuracy rate of T and N staging in csPCa patients, providing a basis for individualized precision diagnosis and treatment.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回